Invicros radiochemistry team has experience with almost all commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:

• A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ
• Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
• 18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
• Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteer

Learn More

We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:

• Syngeneic models
• Human xenograft tumors in immunocompromised mice
• Humanized mouse models
• GEMM mouse model

We also work with larger species including canine, porcine, and non-human primates (NHP).

Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:

• Segmentation
• Image co-registration
• Radiation dosimetry
• Mechanistic pharmacokinetic modeling including PBPK modeling
• Tracer kinetic modeling
• Radiomics
• Imaged-based machine learning
• Full service independent blind reads or collect and hold capabilities
• Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC

Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.

• Focal adhesion kinase inhibitor GSK2256098 (Neuro Oncol. 2018 May 17)
• Lapatinib (EJNMMI Res. 2015 Apr 30;5:30)

Learn More

The medical image analysis team supports standard analysis of FDG PET imaging, including PERCIST and other SUV-based metrics, metabolic tumor volume and total lesion glycolysis. The image analysis team also specializes in developing and applying a broad range of tools to support advanced quantitative oncology tracer characterization and analytics across a broad range of modalities and studies. Some examples include:

• Powerful, multi-modal tumor and organ Segmentation tools
• A range of flexible Biomathematical Modeling tools
• Dosimetry calculations across radionuclide, administration route, and species
• Integrated Radiomics pipelines using standard and custom feature vectors
• Preclinical and clinical support for Tracer Characterization
• Sophisticated batch Image Triage and preprocessing methods

For more information, check out some of our most popular case studies. A full list is also available in our case studies section!

Dosimetry Analysis

Radiomics

Biodistribution

Multi-Modality – Oncology

Learn More